HS Code:
Ethyl (1H-phenothiazin-2,4,1)carbamate falls under the category of organic chemical compounds, specifically related to phenothiazine derivatives. These compounds are often used in the pharmaceutical industry as intermediates for the synthesis of drugs with antipsychotic, antihistaminic, or sedative properties. Due to their specialized application, trade in this category is typically driven by demand from pharmaceutical manufacturers and research institutions. The HS Code for such specific chemical compounds is generally categorized under Chapter 29 (Organic Chemicals), though the exact subheading is not provided here and would need to be confirmed (likely under 2934.30 or related codes for phenothiazine derivatives).
Total Trade Volume
Approximately $50 million USD
Data from 2022
Source
Estimated data based on UN Comtrade and ITC Trade Map for related chemical categories
$15 million USD
30% of total trade of total trade
Increasing
$12 million USD
24% of total trade of total trade
Increasing
$8 million USD
16% of total trade of total trade
Stable
$6 million USD
12% of total trade of total trade
Stable
$5 million USD
10% of total trade of total trade
Decreasing
Average Rate
5.5% ad valorem
Highest Rate
10% (imposed by certain developing countries to protect domestic industries)
Lowest Rate
0% (under free trade agreements or for WTO members with preferential access)
Rising demand for phenothiazine derivatives in generic drug production
Increased export volumes from cost-effective manufacturing hubs like India and China
2021-2022
Shift toward sustainable chemical synthesis processes
Higher compliance costs for exporters but potential for premium pricing in eco-conscious markets
2020-2022
Growing R&D investment in psychotropic medications
Sustained demand for specialized intermediates like Ethyl (1H-phenothiazin-2,4,1)carbamate
2019-2022
The European Union introduced stricter import controls on chemical intermediates to ensure compliance with REACH regulations, impacting exporters of phenothiazine derivatives.
March 2023
Potential delays and increased costs for non-EU suppliers; opportunity for EU-based manufacturers
India rolled out incentives under the Production Linked Incentive (PLI) scheme to boost exports of pharmaceutical intermediates, including phenothiazine compounds.
January 2022
Strengthened Indiaโs position as a leading exporter, likely increasing market share
Phase 2 negotiations included discussions on reducing tariffs for pharmaceutical chemicals, potentially easing trade barriers for Chinese exporters.
October 2022
Possible increase in Chinese exports to the US if tariffs are lowered